Farletuzumab

Summary

Farletuzumab (CHEMBL1743016) is a phase-3 clinical-stage antibody; indicated across 5 conditions including ovarian cancer and lung adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 5 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743016
Name	Farletuzumab
Type	Antibody
Max phase	3

Also known as: Farletuzumab, M3, MORAb-003, FARLETUZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ovarian cancer	3	MONDO:0008170	MONDO:0008170
lung adenocarcinoma	2	MONDO:0005061	EFO:0000571
peritoneal neoplasm	2	MONDO:0006901	EFO:1001100
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	6
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00849667	PHASE3	TERMINATED	Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
NCT00318370	PHASE2	COMPLETED	Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
NCT00738699	PHASE2	TERMINATED	An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
NCT01018563	PHASE2	TERMINATED	An Open Label Extension Study of the Efficacy of MORAb-003
NCT01203618	PHASE2	WITHDRAWN	Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
NCT01218516	PHASE2	COMPLETED	A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
NCT02289950	PHASE2	COMPLETED	A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
NCT00428766	PHASE1	COMPLETED	Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
NCT01049061	PHASE1	COMPLETED	A Study of MORAb-003 in Patients With Solid Tumor

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).